The Filing Desk

MaxCyte vs Precipio

MaxCyte MXCT · Precipio PRPO · Life Sciences Tools & Services

MaxCyte reported revenue of $33 million in fiscal 2025, 1.4 times Precipio's $24 million in fiscal 2025. MaxCyte's revenue fell 14.5% in its latest year, and Precipio's grew 29.8%. MaxCyte had an operating margin of -157.1%, against -5.0% at Precipio. Free cash flow was −$36 million at MaxCyte and $0 million at Precipio.

Side by side

MaxCytePrecipio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$33M$24M
Revenue growth−14.5%29.8%
Revenue growth a year, last 5 years4.7%31.5%
Gross margin81.2%44.5%
Operating margin−157.1%−5.0%
Net margin−135.1%−1.5%
Free cash flow−$36M$0M
Free cash flow margin−109.5%1.5%
Return on capital—−7.8%
Net debt to EBITDA—−37.4x
Dividends and buybacks$0M$0M
Change in diluted share count1.5%9.5%
Last close$1.28$18.49
P/E at the last close——
Insider trades, last 12 monthsbought $120,780, sold $8,316—
Piotroski F-score—7 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MaxCytePrecipio
Operating margin
Percent of revenue
MaxCytePrecipio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MaxCytePrecipio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MaxCyte and Precipio pages.